AMRN
Amarin Corporation plc·Healthcare
14.52
1.538%(+0.22)
Close PriceLast Updated: — ET
52W L: $11.2752W H: $20.90
AMRN NEWS
globenewswire.com
18h ago
New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia
DUBLIN and BRIDGEWATER, N.J., May 27, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) (Amarin), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, today announced new data from a post hoc analysis of the REDUCE-IT® trial presented at the European Atherosclerosis Society (EAS) Congress 2026 in Athens, Greece.
zacks.com
May 8
IOVA Q1 Earnings Match Estimates, Sales Miss, Stock Down 13%
Iovance matches Q1 earnings estimates, but weaker-than-expected Amtagvi and Proleukin sales sent shares down 13% despite revenue growth.
zacks.com
May 5
All You Need to Know About Amarin (AMRN) Rating Upgrade to Strong Buy
Amarin (AMRN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
zacks.com
Apr 30
Amarin's Q1 Loss Narrower Than Expected, Sales Increase Y/Y
AMRN beats earnings and sales estimates as Vascepa sales rise and cost cuts take hold, while the partnered Europe strategy reshapes growth.
seekingalpha.com
Apr 29
Amarin Corporation plc (AMRN) Q1 2026 Earnings Call Transcript
Amarin Corporation plc (AMRN) Q1 2026 Earnings Call Transcript
globenewswire.com
Apr 29
Amarin Reports 2026 First Quarter Financial Results
Total Revenue Increased Led by Higher International Sales Generated Positive Cash Flow and Reiterates Expectation for Full Year Positive Cash Flow Recently Updated Industry Guidelines Expand Global Medical Society Endorsements Supporting the Use of Icosapent Ethyl (IPE) in Contemporary Lipid and Cardiovascular Risk Management DUBLIN, Ireland and BRIDGEWATER, N.J., April 29, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced financial results for the first quarter ended March 31, 2026 (Q1 2026).
